John M. Burke, PhD
Dr. Burke's BS and MS are in Applied Mathematics from the University of Massachusetts, Lowell, in 1993 and 1995, respectively. His PhD degree is in Applied Mathematics from Arizona State University in 2003. His research interests include singularly and randomly perturbed differential equations, bifurcation theory, and applying dynamical systems theory to study and understand how cells and tissues make decisions in humans, and human disease.
Prior to co-founding Applied BioMath, Dr. Burke joined Boehringer Ingelheim in 2008 as Associate Director, Head of Systems Biology. In 2011, he was promoted to Senior Principal Scientist. At Boehringer Ingelheim, he started, developed and managed the Systems Biology group, portfolio, and strategy. The group was responsible for applying systems techniques to the drug discovery process across all Research sites, and supporting Development and Medicine. Prior to Boehringer Ingelheim, Dr. Burke was at Merrimack Pharmaceuticals, Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, HMS, and was a Sr. Postdoctoral Fellow in Douglas A. Lauffenburger's lab, Biological Engineering Department, MIT. While at MIT and HMS, Dr. Burke provided consulting or advising for various companies, including AstraZeneca, Pfizer, Momenta, Matlab, and RES Group. Presently he is an on the advisory boards for the MIT 'Human Physiome on a Chip' MIT-DARPA Program, and the Mathematics Department at the University of Massachusetts, Lowell.
Joshua Apgar, PhD
Before co-founding Applied BioMath Josh was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. His work leveraged physics-based models to: translate in vitro and in vivo data, assess target feasibility, understand drug mechanism of action, and predict human doses. The ultimate goal of this work was to reduce late stage attrition in drug development through a deep and quantitative interrogation of drug pharmacology and disease pathophysiology.
Josh received his PhD from MIT in Biological Engineering where he worked on experiment design for Systems Biology, focusing on the identification of tractable experiments that could allow for the estimation of unknown parameters and reveal complex mechanisms in signal transduction networks. Before that Josh worked at Avaki to develop a highly scalable software platform to support High Performance Computing, and Enterprise Information Integration in the Life Sciences, and Engineering.
Andrew Sutherland, MSc
Andrew brings over 18 years experience in growing and developing financial and operational processes to Applied BioMath. As one of the co-founders, Andrew is responsible for all business matters of Applied BioMath. He has a long track record of successfully driving shareholder value and most recently was head of finance & administration for Litle & Co., which was acquired by Vantiv in 2012. Prior to Litle, Andrew has worked for a number of startups, all in the finance and administration role. Andrew started his career in large, multi-national companies, most notably GTE Internetworking/Genuity where he worked in Strategic Finance and Mergers & Acquisitions, assisting in Genuity's IPO. Andrew received his undergraduate degree from the University of Massachusetts and a Master’s of Science in International Accounting & Finance from The London School of Economics.